Purpose: The National Centre for Epilepsy in Norway admits patients with refractory epilepsy from the whole country. The purpose of this study was to investigate how antiepileptic drugs (AEDs) are used at the centre and compare it with the total consumption in the country and international guidelines regarding clinical use of AEDs. Material and methods: A prevalence study was carried out from patient records from 264 patients (136 adults and 128 children). The use of AEDs, gender, polytherapy, common drug combinations, serum concentration measurements, concomitant medication and comorbid conditions were investigated. Results: Of the 15 AEDs in use, valproate, lamotrigine and levetiracetam were most frequently used. In the country at large, carbamazepine, valproate and lamotrigine were used the most. Valproate and lamotrigine occurred most frequently in combination. In adults, oxcarbazepine and topiramate were used more frequently in women than in men. Children used benzodiazepines three times as often as adults. Newer AEDs were mostly used for partial seizures, in accordance with international guidelines. Thirty-five percent of adults and 20% of children suffered from comorbid CNSrelated conditions. The use of concomitant medication was widespread. Serum concentrations were in accordance to recommended therapeutic ranges.
Introduction
The National Centre for Epilepsy in Norway admits patients with refractory epilepsy from the whole country. Many of the patients have used various antiepileptic drugs (AEDs) and drug combinations without achieving satisfactory seizure control. For this patient group it is of major importance that several new AEDs have become available during the last decade: gabapentin, felbamate, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, vigabatrin, and zonisamide. Older AEDs include carbamazepine, ethosuximide, phenobarbital, phenytoin, valproate, and bezodiazepines such as clonazepam and nitrazepam. Since treatment of epilepsy may be complicated and unsatisfactory, evidence-based guidelines have been developed independently in USA and Europe to summarize what randomized controlled clinical trials have demonstrated and how these results may be used as guidelines for the treatment of epilepsy. [1] [2] [3] [4] The guidelines include recommendations based on the findings for the clinical use of AEDs from newly diagnosed epilepsy and refractory epilepsies, partial and generalized seizures. [1] [2] [3] [4] The purpose of this study was to investigate how AEDs are used at the centre compared to the total use in the country and if the use adhered to international guidelines and recommendations. The assumption was that the centre offers treatment to patients with refractory epilepsy, which reflects the prevailing views and updated international recommendations, that is different from the total use of AEDs in the country as a whole. Special features regarding the treatment of epilepsy in children and adults are focused upon.
Material and methods
A prevalence study was carried out from patient records from 264 inpatients (136 adults and 128 children). The data were collected anonymously and registered in a form every second week during the first 3 months in 2005 and 2006. The average hospital stay was 17 and 10 days for adults and children, respectively. Only in-patients in the actual period were included in the study. Patients already registered were excluded. Drugs for acute use were not included in the study. The AEDs in use were: carbamazepine, clonazepam, gabapentin, lamotrigine, levetiracetam, nitrazepam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, topiramate, valproate, vigabatrin, and zonisamide. Clobazam and sulthiame were unlicensed.
All data were anonymized, by giving each form a number. Year of birth, gender, etiology and reason for admission, and data regarding the use of AEDs and other drugs were registered. The use of AEDs in different patient populations was studied, including children of different age groups, women, men, patients with partial or generalized epilepsies, and patients with comorbid conditions and with concomitant central nervous system (CNS)-related medication. No data could be linked to the individual patient. A patient administration system (DIPS) was used as a quality control of the seizure types, double-registration of patients, and serum concentrations of the AEDs.
Statistics of the total use of AEDs in Norway during the last 25 years were prepared from available data. 5 Newer AEDs were defined as drugs marketed from 1993 and onwards. The study was approved by the local ethical committee. Statistical analysis: a paired, two-tailed t-test was used to investigate statistical difference in the number of AEDs used in adults and children.
Results

Patient population
Characteristics and demographic data regarding the patient population are shown in Table 1 . The patients were admitted from the whole country. The majority of the patients had stayed at the centre previously, and most of them had an established epilepsy diagnosis. Most patients had suffered from epilepsy for several years. In adults, 46% of the patients were admitted for drug adjustments. A total evaluation regarding medical, pedagogical and psychological aspects was common, including evaluations regarding driving licence and psychosocial problems in adults. In children, drug adjustments (43%) in addition to pedagogical and psychological elucidation (38%) were the major reasons for hospitalization. Other reasons for admission were long-term video-EEG monitoring. Neurosurgical work up includes evaluation for epilepsy surgery or implantation of vagal nerve stimulator. The majority of the adults had partial seizure types (Table 1 ). In children, generalized seizure types occurred more often, probably because generalized epilepsy syndromes are predominant in this patient group.
Clinical use of AEDs
Fifteen AEDs were included in the study. In adults, levetiracetam, valproate and lamotrigine were most frequently used at the centre (Fig. 1) . Each of these was used in 30% of the patients. The use of topiramate (24%), oxcarbazepine (19%) and carbamazepine (16%) was also common. Benzodiazepines were used in 14% of the adult patients. In children, valproate, lamotrigine and levetiracetam were most frequently used, in 32%, 25% and 20% of the patients, respectively (Fig. 1) . Topiramate was also frequently used (15%), and benzodiazepines were used in 38% of the patients from 0 to 14 years old. The use of oxcarbazepine, phenytoin, gabapentin, pregabalin, phenobarbital, and zonisamide was limited or absent in children. Vigabatrin and sulthiam were not used in adults.
The total use of AEDs for epilepsy and other indications in Norway during the last 25 years is shown in Fig. 2 . The figure illustrates that carbamazepine has been used most frequently in almost 20 years. From 1993, the use of newer AEDs has gradually increased, and the use of the older drugs, phenobarbital and phenytoin, has decreased since 1980.
Polytherapy with AEDs was common at the centre (Fig. 3) . Totally 170 patients used polytherapy. Adults tended to use more AEDs than children ( Table 1 ). The use of one to two AEDs was most common (30% and 39%, respectively), and three AEDs were more frequently used in adults than in children (Fig. 3 ). Ten percent of the patients used no AED at the time of data collection. In adults, lamotrigine was most often used as monotherapy, while valproate was used most often as monotherapy in children. Table 2 shows the most common combinations of AEDs. There were a great variety of combination therapies in use, but valproate and lamotrigine occurred most often, in 17% of the patients. Furthermore the populations of adults and children are subdivided to show the differences in combinations between these two groups of patients.
Aspects of the use of AEDs in different patient groups
The use of AEDs in children and adults with partial and generalized epilepsy, in patients with comorbid conditions and with concomitant CNS-related medication was studied. The use of AEDs in different age groups in children is illustrated in Fig. 4 . In the youngest children (0-2 years old), valproate was used in 64% of the patients. Valproate was also most 358 C.J. Landmark et al. Figure 1 The use of AEDs in adults (n = 136) and children (n = 128) at the epilepsy centre. commonly used in the next age groups, 40% in the group 3-6 years old and 34% in the group 7-10 years old. In the oldest children (11-14 years old) levetiracetam was used most often (40%). The use of benzodiazepines (clonazepam, clobazam and nitrazepam) was widespread in all age groups (Fig. 4 ). There were no differences in the use of AEDs regarding age in adults (data not shown).
Gender differences in the use of AEDs in adults are shown in Fig. 5 . Newer AEDs with assumed less teratogenic potential were used more frequently in women than in men. Oxcarbazepine was used by 25% and 10%, pregabalin was used by 25% and 11%, and topiramate was used by 24% and 18% in women and men, respectively. Women used levetiracetam, valproate, lamotrigine, topiramate, and oxcarbazepine to a similar extent. There were no gender differences in the use of lamotrigine and levetiracetam. The older AEDs with a known teratogenic potential, valproate, carbamazepine, phenytoin, and phenobarbital, were used more frequently in men than in women. All together, those who used newer AEDs were 91 women and 71 men, while there were 43 women and 67 men using older AEDs (one patient often used more than one drug).
Serum concentrations of AEDs were measured in many of the patients. Therapeutic drug monitoring was used as a tool to optimize the therapy with AEDs, to investigate the expected effect of the drugs and compliance, to discover possible side effects and interactions. 6, 7 The mean serum concentrations are shown in Table 3 and were in accordance with the commonly accepted therapeutic ranges for the various drugs. 6, 7 The serum concentrations in adults and children were very similar (Table 3) . Measurements from patients who underwent dose adjustments at the time of data collection were excluded.
Comorbid conditions and concomitant medication
Thirty-five percent of the patients suffered from comorbid conditions related to CNS and used concomitant medication. The most commonly occurring conditions in adults were psychiatric disorders (Table 4) . Other diagnoses occurred only once, as diabetes, allergy and eczema. In children, 20% of the patients suffered from comorbid conditions in the CNS (Table 4) . Other diagnoses occurring were gastrointestinal disorders (5) and asthma (2) . The use of CNS-related drugs is also listed in Table 4 . 
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Discussion Clinical use of AEDs
Valproate, lamotrigine and levetiracetam were the three most frequently used drugs at the centre and this differs from the use in the country at large. Carbamazepine, lamotrigine and valproate are the three most frequently used in Norway, where carbamazepine has been the leading drug for almost 20 years, and levetiracetam is used limited. At the centre, new AEDs are used more extensively than the older drugs. It is, however, surprising that levetiracetam which was marketed in 2001, is so commonly used. The oldest drugs, phenobarbital and phenytoin have a limited use at the centre, but they are still used to some degree in the country as a whole, most probably in the 'older' patient groups. There may be several reasons for such an extensive use of new AEDs. Several studies have demonstrated that the new drugs are equally effective to the older ones, and that several of the new drugs have a better side effect profile and lower risk of interactions. 1, 2, 8, 9 At the epilepsy centre there are more patients with refractory epilepsies than in other hospitals. Many of these patients may have tried the older drugs without achieving satisfactory seizure control. It is therefore reasonable that the new drugs are first tried in this patient group.
The use of valproate, lamotrigine and levetiracetam was most extensive, probably due to their broad spectrum effects, both in partial and generalized seizures, and as mono-and polytherapy. The same drugs were used most often at the centre as a whole, and the use of AEDs at the centre differs from the rest of the country (Figs. 1 and 2 ). In the country at large, the use of valproate increased until 2002 but has levelled out since then. The use of lamotrigine has increased from 1994 when it was marketed. The increase seen with both drugs is probably a result of extensive use in non-epilepsy disorders like bipolar disorder, mania, neuropathic pain and migraine. 10, 11 At the centre, carbamazepine and oxcarbazepine were used the same extent, while in the whole country carbamazepine is used six times as often as oxcarbazepine. The use of carbamazepine is decreasing, while oxcarbazepine is increasing (Fig. 2) . This is also seen in the use of these drugs 360 C.J. Landmark et al. Figure 4 The use of AEDs in children (n = 128), related to age. The children often used more than one AED. Children from 0 to 2 years (n = 11), 3-6 years (n = 25), 7-10 years (n = 41) and 11-14 years old (n = 37).
in Denmark, where oxcarbazepine is the preferred drug of the two (in 2005 1.8 and 1.5 DDD/1000 inhabitants/day) for oxcarbazepine and carbamazepine, respectively. 12 The two drugs have similar anticonvulsive effects, while oxcarbazepine has a more favourable side effect profile and lower risk of interactions than carbamazepine. 9 The use of gabapentin was limited in the present study, while the use of the newer analogue, pregabalin, was more extensive (in adults) as this drug was recently introduced. Both drugs are widely used to treat neuropathic pain. Benzodiazepines were mostly frequently used in children. This may reflect their refractory epilepsies, but the doses used were often low. The older children used AEDs similar to the adults, i.e., levetiracetam and topiramate.
The mechanisms of action of the various AEDs should be of importance for the proper choice of drug, although it is still not fully known what criteria that should be taken into account. Many AEDs affect the balance between the excitatory neurotransmitter glutamate and the inhibitory transmitter GABA, and they decrease neuronal excitability. 8, 13, 14 Most of the AEDs possess multiple mechanisms of action and may therefore have sevClinical use of antiepileptic drugs 361 Figure 5 The use of AED related to gender in adult patients (n = 136), men (n = 61) and women (n = 75). Anxiolytics (14); antidepressants (10); neuroleptics (10); sedatives (8); melatonin (3) Cerebral palsy (7) Psychogenic non-epileptic seizures (6) Migraine (2) Children Melatonin (29); spasmolytics (11) Cerebral palsy (9) Attention deficit hyperactivity disorder (ADHD) (7) Methylphenidate and atomexetine (10) Developmental disorders (5) Mental retardation (2) Down syndrome (2) a The number of patients is given in parenthesis.
eral targets in the synapse to decrease epileptic activity. Because of their broad spectrum of activity, many AEDs are now used in other disorders than epilepsy, including bipolar disorder, schizophrenia, neuropathic pain, migraine, anxiety and tremor, and other conditions are under investigation. 11, 15 This should also be taken into account when considering the proper treatment for patients with comorbid conditions.
Polytherapy, comorbid conditions and concomitant medication
The combination of valproate and lamotrigine occurred most frequently. The use of this combination is advantageous due to a synergistic effect. 16 Polytherapy was used more often in adults than in children, probably since many adults have had refractory epilepsy for several years and have tried a number of AEDs. Benzodiazepines were often used in the children in addition to one main AED, for instance valproate.
Comorbid conditions were seen in many of the patients, and AEDs may also be preferred drugs in several of these disorders, as in anxiety, bipolar disorder, and migraine, since it is assumed that many of these disorders may share common pathophysiological pathways. 10 Therapeutic drug monitoring is often helpful to prevent adverse effects and potential for interactions with concomitant use of other CNS-active drugs.
The use of AEDs in women and men
The present study shows that women used new AEDs to a greater extent than men. There were more women who used oxcarbazepine and topiramate, while men used drugs like valproate, carbamazepine and phenytoin, AEDs with a known teratogenic potential. [8] [9] [10] Most of the women in the study were in fertile age, and fear of teratogenic effects and risk of pharmacokinetic interactions with peroral contraceptives may be decisive for the choice of drug. Carbamazepine and phenytoin reduce the effect of oral contraceptives due to enzyme induction, while the serum concentration of lamotrigine may be reduced by 50% with concomitant use of peroral contraceptives with estrogen derivatives. 17, 18 In higher doses oxcarbazepine and topiramate also seem to have interactions with oral contraceptives. 19, 20 Since the AEDs were monitored by the measurements of serum concentrations, possible interactions with these contraceptives in female patients were probably taken into account for by adjusting the dose of lamotrigine. Topiramate may lead to weight loss, which may be favourable for patients with a weight problem.
Are the results in accordance with international guidelines?
The evidence-based guidelines from USA suggest that all the new AEDs may be used in partial epilepsies in adults with refractory epilepsy. Lamotrigine, topiramate, and oxcarbazepine may be used as monotherapy, but they cannot be recommended for primary generalized epilepsies at the highest guidelines levels A or B.
2 As a majority of the adults suffered from partial epilepsies in the present study and may be regarded as having refractory epilepsies, the use of drugs seems to be in good accordance with these guidelines. In newly diagnosed epilepsy, the newer AEDs gabapentin, lamotrigine, topiramate, and oxcarbazepine are recommended as monotherapy or mixed, while only lamotrigine is recommended in absence epilepsy. 1 In the present study, all of these drugs except gabapentin, were used to a large extent, keeping in mind that most patients had suffered from epilepsy for several years. The recommendation from the evidencebased guidelines in the pediatric population with refractory epilepsy by French et al. 1, 2 suggest that gabapentin, lamotrigine, topiramate, and oxcarbazepine may be used in partial seizures, but the use of gabapentin and oxcarbazepine was limited in the present study.
The International League against epilepsy (ILAE) prepared guidelines for initial monotherapy for epilepsy, for adults, children and elderly patients with partial-, generalized tonic-clonic-or absence seizures.
Limitations of the study
Regarding methodological considerations, a prevalence study maps the use of drugs at a specific time point, and therapy adjustments, optimalized treatment or outcome of a visit at the epilepsy centre are not registered or discussed. Data from most of the hospitalized patients in the period of data collection were included, but the material does not give a total picture of the use of AEDs at the centre, since some patients with short stays would be in and out between two time points of collection. Nevertheless, the material gives information about the pattern of pharmacotherapy with AEDs and may be compared to the total use in the country and to international guidelines. The data regarding the total consumption of AEDs in the country (Fig. 2) reflect the use of AEDs in epilepsy and also other indications, but a further subdivision of the data is not available. These data are given in DDD/1000 inhabitants per day and are therefore not directly comparable to the number of patients that are used in the present study. The use of AEDs at the centre and in the whole country can only be compared as their appearance in consecutive order, as which one is used the most, the second and so on. Despite of this limitation it gives us the opportunity to point to differences in trends in use of the different AEDs.
Many patients underwent drug adjustments at the time of data collection that possibly led to an overestimation of polytherapy. This may be seen in some of the cases with three to five AEDs, where probably a new drug is being escalated before another one is withdrawn. The majority of the patients used polytherapy since the patients admitted to the centre have refractory epilepsies, and they may have tried monotherapy unsuccessfully. Optimal serum concentrations were not always possible to determine under the study conditions due to short stays for drug adjustments, which would affect the mean serum values.
Conclusion
Valproate, levetiracetam, lamotrigine, and topiramate were used most frequently. The results show that newer AEDs are more frequently used at the centre than in the rest of the country. Women used new AEDs to a larger extent than men. All of the new AEDs were mainly used for partial seizures. Valproate and lamotrigine was the most commonly used combination. The use of polytherapy was extensive, and therapeutic drug monitoring was used to optimize drug treatment in the individual patient. Children >11 years used new AEDs similar to adults, while the younger children used benzodiazepines more often. The use of AEDs at the centre was in accordance with international guidelines and recommendations, and this could serve as a reference for other prescribers.
